Ir. Ellen Schmitz
Ellen Schmitz got her bachelor’s degree in Biomedical Engineering from the Eindhoven University of Technology (TU/e) in 2010. After that, she spent one year as a member of the board of Biomedical Engineering’s study association “Protagoras”. To learn more about biomedical engineering in a clinical setting, she continued with a master’s degree in Medical Engineering, a collaboration between the TU/e and Maastricht University. The research for her Master thesis was conducted at the clinical laboratory of the Catharina hospital in Eindhoven. She developed an LC-MS/MS method for quantification of three novel oral anticoagulants. This method served as a gold standard technique for comparison of several coagulation assays, which are used more traditionally in clinical labs but are analytically inferior. For her internship she went to San Francisco, to study reprogramming of endothelial cells using iPS technology in Ann Zovein’s lab (UCSF). She received her master’s degree in 2013.
Currently, she is a PhD student in the field of clinical chemistry, with prof. Volkher Scharnhorst and prof. Luc Brunsveld. This project is a collaboration between the laboratory of Chemical Biology at the TU/e and the clinical labs of the Catharina Hospital Eindhoven and Máxima Medical Center Veldhoven. This collaboration optimally enables the combination of medical expertise and state-of-the art technology to solve clinical problems. Projects include the analysis of existing methods and development of new methods for quantification of infliximab, a therapeutic anti-TNFα antibody used to treat inflammatory disorders; and development of an LC-MS/MS method to quantify hepcidin, a key peptide hormone in iron regulation.